Inactief instrument

Andere talen Cellectar Biosciences Inc Nasdaq

Aandelen

US15117F3029

Andere talen

Krijg toegang tot al het nieuws: wees als eerste op de hoogte en reageer voordat de beurs dat doet!

Cellectar Biosciences, Inc.(NasdaqCM:CLRB) added to Russell 3000E Index	01/07
Cellectar Biosciences, Inc.(NasdaqCM:CLRB) added to Russell Microcap Index	01/07
Cellectar Biosciences, Inc.(NasdaqCM:CLRB) added to Russell Microcap Growth Index	01/07
Cellectar Biosciences, Inc.(NasdaqCM:CLRB) added to Russell 3000E Growth Index	01/07
Cellectar Biosciences, Inc.(NasdaqCM:CLRB) added to Russell Microcap Value Index	01/07
Cellectar Biosciences, Inc.(NasdaqCM:CLRB) added to Russell 3000E Value Index	01/07
Cellectar Biosciences to Host Key Opinion Leader Event to Review the Full Results from Its CLOVER WaM Pivotal Trial and Waldenstrom's Macroglobulinemia Market Landscape	28/06
Cellectar Biosciences to Host Key Opinion Leader Event to Review the Full Results from Its CLOVER WaM Pivotal Trial and Waldenstrom’s Macroglobulinemia Market Landscape	27/06
Cellectar Biosciences and City of Hope Cancer Center Enter Collaboration to Evaluate Iopofosine I 131 in Mycosis Fungoides	29/05
Cellectar Biosciences, Inc. and City of Hope Cancer Center Enter Collaboration to Evaluate Iopofosine I 131 in Mycosis fungoides	29/05
Cellectar Biosciences Reports Financial Results for Q1 2024 and Provides a Corporate Update	14/05
Cellectar Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05
Cellectar Biosciences to Present at the Guggenheim Healthcare Talks Radiopharmaceuticals Day	08/05
Cellectar Biosciences to Announce First Quarter Financial Results and Host a Conference Call on Tuesday, May 14, 2024	07/05
Cellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate Update	27/03
Cellectar Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/03
Cellectar Biosciences to Announce 2023 Year End Earnings Results and Host a Conference Call on Wednesday, March 27, 2024	20/03
Cellectar Biosciences : Corporate Presentation - March 2024	18/03
Cellectar Biosciences to Present at the 36th Annual Roth Conference	14/03
Cellectar Biosciences Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of Iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer	04/03

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Cellectar Biosciences Inc Nasdaq

Aandelen

US15117F3029

Andere talen

Filters